Your browser does not support JavaScript! ORACIT (CITRIC ACID AND SODIUM CITRATE) SOLUTION [CAROLINA MEDICAL PRODUCTS COMPANY]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

ORACIT (citric acid and sodium citrate) solution
[Carolina Medical Products Company]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL unapproved drug other
NOTE:THIS DRUG HAS NOT BEEN FOUND BY FDA TO BE SAFE AND EFFECTIVE, AND THIS LABELING HAS NOT BEEN APPROVED BY FDA. For further information about unapproved drugs, click here.
Drug Label Sections

DESCRIPTION

The product is a clear, colorless solution containing Citric Acid USP 640 mg/5 mL, and Hydrous Sodium Citrate USP 490 mg/5 mL. It also contains Methylparaben NF and Propylparaben NF as preservatives. These concentrations yield 1 mEq of sodium, equivalent to 1 mEq of bicarbonate per mL of solution.

ACTION

Oral citrate solution is used as a systemic and urinary alkalinizer. Less than 5% of the citrate is excreted in the urine unchanged, since citrate oxidation is to a great extent complete.

INDICATIONS

ORACIT® is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). ORACIT® is also effective in treatment for acidosis of certain renal tubular disorders.

CONTRAINDICATIONS

ORACIT® is contraindicated in patients with severe renal impairment, oliguria or azotemia, untreated Addison’s disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.

PRECAUTIONS

The citrate solution should be used with caution in patients with impaired renal function to avoid hypernatremia or alkalosis in the presence of hypocalcemia. Periodic determinations of serum electrolyte levels (especially bicarbonate levels) should be done in patients with renal disease to avoid cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy. The solution should be diluted with water and preferably taken after meals to avoid saline laxative effects.

ADVERSE REACTIONS

Citrate solution is generally well tolerated when given in recommended doses when the patient has normal renal functions.

DOSAGE AND ADMINISTRATION

The dose of ORACIT® is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve desired effects.

HOW SUPPLIED

ORACIT® is supplied in 500 mL bottles (NDC 46287-014-01), 30 mL unit dose bottles, 10 bottles per carton (NDC 46287-014-30), and 15 mL unit dose bottles, 10 bottles per carton (NDC 46287-014-15).

PHARMACIST

Dispense in well-closed containers.

STORE AT CONTROLLED ROOM TEMPERATURE (15° - 30° C)

Company Logo

Carolina Medical Products Co.

Post Office Box 147

Farmville, North Carolina 27828

Revised May 1986

Copyright © Carolina Medical Products Co. 1985

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - BOTTLE LABEL

Bottle Lablel

Bottle Label

NDC 48287-014-01

500 mL

ORACIT®

ORAL CITRATE (SHOHL'S) SOLUTION

Contains: Hydrous Sodium Citrate USP 490 mg/5mL; Citric Acid USP 640 mg/5mL; Methylparaben NF; Propylparaben NF; Alcohol 0.25%

CAUTION: Federal law prohibits dispensing without prescription.

USUAL DOSAGE: See package insert.

DISPENSE IN A WELL-CLOSED CONTAINER.

STORE AT CONTROLLED ROOM TEMPERATURE 15° - 30° C (59° - 86° F).

BATCH:

EXP:

 

Carolina Medical Products Co.

Post Office Box 147

Farmville, North Carolina 27828

ORACIT 
citric acid and sodium citrate solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:46287-014
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CITRIC ACID MONOHYDRATE (ANHYDROUS CITRIC ACID) CITRIC ACID MONOHYDRATE640 mg  in 5 mL
TRISODIUM CITRATE DIHYDRATE (ANHYDROUS CITRIC ACID) TRISODIUM CITRATE DIHYDRATE490 mg  in 5 mL
Inactive Ingredients
Ingredient NameStrength
METHYLPARABEN 
PROPYLPARABEN 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:46287-014-01500 mL in 1 BOTTLE
2NDC:46287-014-3010 in 1 CARTON
230 mL in 1 BOTTLE, UNIT-DOSE
3NDC:46287-014-1510 in 1 CARTON
315 mL in 1 BOTTLE, UNIT-DOSE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other05/15/1984
Labeler - Carolina Medical Products Company (005224175)

Revised: 9/2012
 
Carolina Medical Products Company

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services